Royalty Pharma is a leading company in acquiring pharmaceutical royalties across the life sciences industry. They fund innovation in the biopharmaceutical industry by partnering with companies to co-develop and co-fund late-stage clinical trials. With a flexible approach to acquisitions, Royalty Pharma is transforming the funding of life sciences.

UPDATED: Royalty Pharma tops its record-setting $3.3B deal with CF Foundation, betting $575M more on Vertex's drugs | @CF_Foundation @VertexPharma...

Royalty Pharma has acquired our royalty interest in Amgen's olpasiran for $250M in cash upfront + up to $160M in additional payments.

Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co- ...

Royalty Pharma

Find contacts at this company